SCHEMBL29357645

SCHEMBL29357645

CCOc1ccc2ccccc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGXT P21549 2/20 0.63
MAPK1 P28482 2/20 0.62
TDP1 Q9NUW8 2/20 0.62
GAA P10253 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
KDM4E B2RXH2 1/20 0.61
ALOX5 P09917 1/20 0.59
CYP1A2 P05177 2/20 0.58
CYP2A6 P11509 1/20 0.58
NQO1 P15559 1/20 0.56
PTPN7 P35236 1/20 0.55
RAB9A P51151 2/20 0.54
POLB P06746 1/20 0.54
LTA4H P09960 1/20 0.54
RELA Q04206 1/20 0.53
CYP19A1 P11511 1/20 0.53
CYP11B1 P15538 1/20 0.53
CYP11B2 P19099 1/20 0.53
NPC1 O15118 1/20 0.52
MAPT P10636 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL111274 1.00 AGXT (0.63) AGXTMAPK1TDP1GAAL3MBTL1
SCHEMBL30209608 1.00 AGXT (0.63) AGXTMAPK1TDP1GAAL3MBTL1
SCHEMBL17629449 1.00 AGXT (0.63) AGXTMAPK1TDP1GAAL3MBTL1
SCHEMBL27786463 0.98 AGXT (0.61) AGXTMAPK1TDP1GAAL3MBTL1
SCHEMBL27786466 0.98 AGXT (0.61) AGXTMAPK1TDP1GAAL3MBTL1
SCHEMBL27786460 0.98 AGXT (0.61) AGXTMAPK1TDP1GAAL3MBTL1
Methyl Alcohol SCHEMBL27786467 0.96 AGXT (0.59) AGXTMAPK1TDP1GAAL3MBTL1
Formaldehyde SCHEMBL28727752 0.94 MAPK1 (0.61) AGXTMAPK1TDP1GAAL3MBTL1
Ether SCHEMBL17634330 0.94 MAPK1 (0.60) AGXTMAPK1TDP1GAAL3MBTL1
SCHEMBL19910986 0.92 CYP11B1 (0.64) AGXTMAPK1TDP1GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600926-B2 Treatment compositions with modified amino acid dimers for delivering a benefit agent THE PROCTER & GAMBLE COMPANY (US) 2026-04-14 US claimed
US-20260000592-A1 TREATMENT COMPOSITIONS WITH ESTERAMINES OR SALTS THEREOF PROCTER & GAMBLE (US) 2026-01-01 US claimed
US-12509643-B2 Pro-benefit-agent compounds with carbon/nitrogen bonds THE PROCTER & GAMBLE COMPANY (US) 2025-12-30 US claimed
US-20250302678-A1 ABSORBENT ARTICLES INCLUDING PERFUME AND CYCLODEXTRINS PROCTER & GAMBLE (US) 2025-10-02 US claimed
EP-4581114-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Novozymes A/S (DK) 2025-07-09 EP claimed
US-12350136-B2 Absorbent articles including perfume and cyclodextrins THE PROCTER & GAMBLE COMPANY (US) 2025-07-08 US claimed
US-20250163343-A1 FRAGRANCE COMPOSITIONS FOR SLEEP IMPROVEMENT INTERNATIONAL FLAVORES & FRAGRANCES INC. 2025-05-22 US claimed
EP-3325588-B1 PERFUME COMPOSITIONS GIVAUDAN SA (CH) 2025-04-16 EP claimed
CN-119698458-A Improvements in or relating to organic compounds improvements relating to organic compounds 诺维信公司 2025-03-25 CN claimed
WO-2025051371-A1 A FRAGRANCE PASTILLE SYMRISE AG (DE) 2025-03-13 WO claimed
US-20230002330-A1 PRO-BENEFIT-AGENT COMPOUNDS WITH HETEROCYCLIC MOIETIES THE PROCTER & GAMBLE COMPANY 2023-01-05 US claimed
US-20220403297-A1 PRO-BENEFIT-AGENT COMPOUNDS WITH CARBON/NITROGEN BONDS THE PROCTER & GAMBLE COMPANY 2022-12-22 US claimed
US-20220401275-A1 ABSORBENT ARTICLES INCLUDING PERFUME AND CYCLODEXTRINS PROCTER & GAMBLE (US) 2022-12-22 US claimed
WO-2022251818-A1 PRO-BENEFIT-AGENT COMPOUNDS WITH HETEROCYCLIC MOIETIES THE PROCTER & GAMBLE COMPANY (US) 2022-12-01 WO claimed
WO-2022251817-A1 PRO-BENEFIT AGENT COMPOUNDS WITH CARBON/NITROGEN BONDS THE PROCTER & GAMBLE COMPANY (US) 2022-12-01 WO claimed
WO-2022214636-A1 FRAGRANCE COMPOSITION GIVAUDAN SA (CH) 2022-10-13 WO claimed
US-11458049-B2 Absorbent articles including perfume and cyclodextrins THE PROCTER & GAMBLE COMPANY (US) 2022-10-04 US claimed
WO-2022129351-A1 A SYNERGISTIC PERFUMING COMPOSITION FIRMENICH SA (CH) 2022-06-23 WO claimed
WO-2022126093-A1 TREATMENT COMPOSITIONS WITH PRO-FRAGRANCE SILICONE POLYMERS THAT COMPRISE HETEROCYCLIC MOIETIES THE PROCTER & GAMBLE COMPANY (US) 2022-06-16 WO claimed
US-20220177813-A1 TREATMENT COMPOSITIONS WITH PRO-FRAGRANCE SILICONE POLYMERS THAT COMPRISE HETEROCYCLIC MOIETIES THE PROCTER & GAMBLE COMPANY 2022-06-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509643-B2 Pro-benefit-agent compounds with carbon/nitrogen bonds HGFAC, PROKR1, FABP2 AGXT 675/4885MAPK1 2688/4885TDP1 4534/4885
US-20260000592-A1 TREATMENT COMPOSITIONS WITH ESTERAMINES OR SALTS THEREOF ARGLU1, DAO, PNISR AGXT 250/4885MAPK1 958/4885TDP1 1734/4885
US-12600926-B2 Treatment compositions with modified amino acid dimers for delivering a benefit agent F2, C9, S100A8 AGXT 558/4885MAPK1 4549/4885TDP1 3522/4885
US-20230002330-A1 PRO-BENEFIT-AGENT COMPOUNDS WITH HETEROCYCLIC MOIETIES PLG, PAM, PREP AGXT 109/4885MAPK1 3032/4885TDP1 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.